| Summary of interests in associates |
| | | | | | | | | | | Interests in associates | | | | | | | | | | | in € K, except where otherwise specified | | | | | | | | | | | | | Country of | | Ownership | | Method of | | | | | Name of the entity | | incorporation | | interest in % | | measurement | | Carrying value | | | | | | | | | 2025 | | 2024 | | | | | | | | | | | | Vifor Fresenius Medical Care Renal Pharma Ltd. | | Switzerland | | 45 | | Equity method | | 632,026 | | 580,973 | Other associates | | | | | | | | 31,626 | | 39,858 | Equity method investees | | | | | | | | 663,652 | | 620,831 |
|
| Summary of summarized financial information of associates |
| | | | | Summarized financial information | | | | | In € K | | | | | Summarized balance sheets | | 2025 | | 2024 | | | | | | Current assets | | 824,062 | | 914,502 | Non-current assets | | 439,909 | | 518,589 | Current liabilities | | 277,103 | | 480,640 | Non-current liabilities | | 32,534 | | 34,116 | Net assets | | 954,334 | | 918,335 |
| | | | | Reconciliation to carrying amounts (net assets) | | 2025 | | 2024 | | | | | | Opening balance net assets January 1, | | 918,335 | | 893,505 | Profit for the period | | 456,306 | | 290,766 | Other comprehensive income | | (3,428) | | (116,914) | Dividends paid | | (304,832) | | (205,301) | Foreign currency translation | | (112,047) | | 56,279 | Closing balance net assets December 31, | | 954,334 | | 918,335 | | | | | | Company’s share in net assets | | 429,450 | | 413,251 | Other reconciling items(1) | | 257,528 | | 219,166 | Eliminations | | (54,952) | | (51,444) | Carrying amount | | 632,026 | | 580,973 |
| | | | | | | For the year ended | | For the year ended | Summarized statement of comprehensive income | | December 31, 2025 | | December 31, 2024 | | | | | | Revenue | | 950,888 | | 741,183 | Profit from continuing operations | | 456,306 | | 290,766 | Profit for the period | | 456,306 | | 290,766 | Other comprehensive income | | (3,428) | | (116,914) | Total comprehensive income | | 452,878 | | 173,852 | | | | | | Dividends received | | 137,174 | | 92,386 |
| (1) | Includes Goodwill as well as impacts from foreign currency translation. |
|